These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 9730445)

  • 1. Serum percent free prostate-specific antigen in metastatic prostate cancer.
    Lin DW; Noteboom JL; Blumenstein BA; Ellis WJ; Lange PH; Vessella RL
    Urology; 1998 Sep; 52(3):366-71. PubMed ID: 9730445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA.
    Grossklaus DJ; Smith JA; Shappell SB; Coffey CS; Chang SS; Cookson MS
    Urol Oncol; 2002; 7(5):195-8. PubMed ID: 12644216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH; Morgan TO; McLeod DG; Moul JW; Murphy GP; Barren R; Sesterhenn IA; Mostofi FK
    Cancer; 1997 Jul; 80(1):107-14. PubMed ID: 9210715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
    Steuber T; Vickers AJ; Haese A; Becker C; Pettersson K; Chun FK; Kattan MW; Eastham JA; Scardino PT; Huland H; Lilja H
    Int J Cancer; 2006 Mar; 118(5):1234-40. PubMed ID: 16152616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer.
    Naya Y; Fritsche HA; Cheli CD; Stamey TA; Bartsch G; Brawer MK; Childs S; Taneja SS; Lepor H; Partin AW; Sokoll LJ; Chan DW; Babaian RJ
    Urology; 2003 Dec; 62(6):1058-62. PubMed ID: 14665355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays.
    Vessella RL; Lange PH; Partin AW; Chan DW; Sokoll LJ; Sasse EA; Crawford ED
    Urology; 2000 Jun; 55(6):909-14. PubMed ID: 10840107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy--a critical assessment.
    Brändle E; Hautmann O; Bachem M; Kleinschmidt K; Gottfried HW; Grünert A; Hautmann RE
    Urology; 1999 Apr; 53(4):722-30. PubMed ID: 10197847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
    Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer.
    Björk T; Lilja H; Christensson A
    BJU Int; 1999 Dec; 84(9):1021-7. PubMed ID: 10571627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percent free prostate-specific antigen values in men with recurrent prostate cancer after radical prostatectomy.
    Wojno KJ; Vashi AR; Schellhammer PF; Wright GL; Montie JE
    Urology; 1998 Sep; 52(3):474-8. PubMed ID: 9730464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
    Catalona WJ; Southwick PC; Slawin KM; Partin AW; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Loveland KG; Bray KR
    Urology; 2000 Aug; 56(2):255-60. PubMed ID: 10925089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Values of prostate specific antigen in patients with operable prostate carcinoma.
    Obralic N; Kulovac B; Aganovic D; Junuzovic D
    Med Arh; 2009; 63(1):34-7. PubMed ID: 19419125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
    Bruun L; Björk T; Lilja H; Becker C; Gustafsson O; Christensson A
    Nephrol Dial Transplant; 2003 Mar; 18(3):598-603. PubMed ID: 12584285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
    J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.